Adicet Bio to Participate in a Fireside Chat at the 2025 Jefferies Global Healthcare Conference

Audio By Carbonatix

REDWOOD CITY, Calif. & BOSTON--(BUSINESS WIRE)--May 21, 2025--

Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced that Chen Schor, President and Chief Executive Officer, will participate in a fireside chat at the Jefferies Global Healthcare Conference being held from June 3-5, 2025 in New York.

Details of the event are as follows:
Date: Wednesday, June 4, 2025
Time: 4:20 p.m. ET

The live audio webcast can be accessed on the Investors section of Adicet Bio’s website at http://www.adicetbio.com. An archived replay will be available for 30 days following the presentation.

About Adicet Bio, Inc.

Adicet Bio, Inc. is a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. Adicet is advancing a pipeline of “off-the-shelf” gamma delta T cells, engineered with chimeric antigen receptors (CARs), to facilitate durable activity in patients. For more information, please visit our website at https://www.adicetbio.com.

View source version on businesswire.com:https://www.businesswire.com/news/home/20250521914133/en/

CONTACT: Adicet Bio., Inc.

Investor and Media ContactsAnne Bowdidge

[email protected] Belnap

Precision AQ

[email protected]

KEYWORD: UNITED STATES NORTH AMERICA CALIFORNIA MASSACHUSETTS

INDUSTRY KEYWORD: BIOTECHNOLOGY HEALTH GENETICS PHARMACEUTICAL ONCOLOGY

SOURCE: Adicet Bio, Inc.

Copyright Business Wire 2025.

PUB: 05/21/2025 04:00 PM/DISC: 05/21/2025 03:59 PM

http://www.businesswire.com/news/home/20250521914133/en